Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection

José M. Gatell; J. M. Miró; E. Aznar; X. Camé; V. Moreno; X. Vidal; D. Podzamczer; F. Gudiol; A. Casanova; B. Clotet; A. Jou; J. M. Miró; J. M. Gatell; E. Aznar; J. M.Martinez Vázquez; I. Ocaña; I. Ruiz Camps; R. Cisterna; J. M. Santamaria; J. Cosín; J. Gómez; J. J. Vázquez; A. Gil Aguado; M. E. Valencia; L. Buzón; J. M.González Lahoz; R. M. Polo; V. Moreno; D. Zulaica; F. Rodriguez Arrondo

doi:10.1016/0140-6736(91)90003-8

Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection

José M. Gatell, J. M. Miró, E. Aznar, X. Camé, V. Moreno, X. Vidal, D. Podzamczer, F. Gudiol, A. Casanova, B. Clotet, A. Jou, J. M. Miró, J. M. Gatell, E. Aznar, J. M.Martinez Vázquez, I. Ocaña, I. Ruiz Camps, R. Cisterna, J. M. Santamaria, J. CosínJ. Gómez, J. J. Vázquez, A. Gil Aguado, M. E. Valencia, L. Buzón, J. M.González Lahoz, R. M. Polo, V. Moreno, D. Zulaica, F. Rodriguez Arrondo

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

18 Citations (Scopus)

Abstract

© 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.

Original language	English
Pages (from-to)	6-9
Journal	Default journal
Volume	338
Issue number	8758
DOIs	https://doi.org/10.1016/0140-6736(91)90003-8
Publication status	Published - 1 Jan 1991

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1016/0140-6736(91)90003-8

Fingerprint Dive into the research topics of 'Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection'. Together they form a unique fingerprint.

Cite this

Gatell, J. M., Miró, J. M., Aznar, E., Camé, X., Moreno, V., Vidal, X., Podzamczer, D., Gudiol, F., Casanova, A., Clotet, B., Jou, A., Miró, J. M., Gatell, J. M., Aznar, E., Vázquez, J. M. M., Ocaña, I., Camps, I. R., Cisterna, R., Santamaria, J. M., ... Arrondo, F. R. (1991). Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Default journal, 338(8758), 6-9. https://doi.org/10.1016/0140-6736(91)90003-8

Gatell, José M. ; Miró, J. M. ; Aznar, E. ; Camé, X. ; Moreno, V. ; Vidal, X. ; Podzamczer, D. ; Gudiol, F. ; Casanova, A. ; Clotet, B. ; Jou, A. ; Miró, J. M. ; Gatell, J. M. ; Aznar, E. ; Vázquez, J. M.Martinez ; Ocaña, I. ; Camps, I. Ruiz ; Cisterna, R. ; Santamaria, J. M. ; Cosín, J. ; Gómez, J. ; Vázquez, J. J. ; Aguado, A. Gil ; Valencia, M. E. ; Buzón, L. ; Lahoz, J. M.González ; Polo, R. M. ; Moreno, V. ; Zulaica, D. ; Arrondo, F. Rodriguez. / Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. In: Default journal. 1991 ; Vol. 338, No. 8758. pp. 6-9.

@article{f4bff7bfe2ba4afda81f1092ca21219d,

title = "Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection",

abstract = "{\textcopyright} 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.",

author = "Gatell, {Jos{\'e} M.} and Mir{\'o}, {J. M.} and E. Aznar and X. Cam{\'e} and V. Moreno and X. Vidal and D. Podzamczer and F. Gudiol and A. Casanova and B. Clotet and A. Jou and Mir{\'o}, {J. M.} and Gatell, {J. M.} and E. Aznar and V{\'a}zquez, {J. M.Martinez} and I. Oca{\~n}a and Camps, {I. Ruiz} and R. Cisterna and Santamaria, {J. M.} and J. Cos{\'i}n and J. G{\'o}mez and V{\'a}zquez, {J. J.} and Aguado, {A. Gil} and Valencia, {M. E.} and L. Buz{\'o}n and Lahoz, {J. M.Gonz{\'a}lez} and Polo, {R. M.} and V. Moreno and D. Zulaica and Arrondo, {F. Rodriguez}",

year = "1991",

month = jan,

day = "1",

doi = "10.1016/0140-6736(91)90003-8",

language = "English",

volume = "338",

pages = "6--9",

number = "8758",

}

Gatell, JM, Miró, JM, Aznar, E, Camé, X, Moreno, V, Vidal, X, Podzamczer, D, Gudiol, F, Casanova, A, Clotet, B, Jou, A, Miró, JM, Gatell, JM, Aznar, E, Vázquez, JMM, Ocaña, I, Camps, IR, Cisterna, R, Santamaria, JM, Cosín, J, Gómez, J, Vázquez, JJ, Aguado, AG, Valencia, ME, Buzón, L, Lahoz, JMG, Polo, RM, Moreno, V, Zulaica, D & Arrondo, FR 1991, 'Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection', Default journal, vol. 338, no. 8758, pp. 6-9. https://doi.org/10.1016/0140-6736(91)90003-8

Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. / Gatell, José M.; Miró, J. M.; Aznar, E.; Camé, X.; Moreno, V.; Vidal, X.; Podzamczer, D.; Gudiol, F.; Casanova, A.; Clotet, B.; Jou, A.; Miró, J. M.; Gatell, J. M.; Aznar, E.; Vázquez, J. M.Martinez; Ocaña, I.; Camps, I. Ruiz; Cisterna, R.; Santamaria, J. M.; Cosín, J.; Gómez, J.; Vázquez, J. J.; Aguado, A. Gil; Valencia, M. E.; Buzón, L.; Lahoz, J. M.González; Polo, R. M.; Moreno, V.; Zulaica, D.; Arrondo, F. Rodriguez.

In: Default journal, Vol. 338, No. 8758, 01.01.1991, p. 6-9.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection

AU - Gatell, José M.

AU - Miró, J. M.

AU - Aznar, E.

AU - Camé, X.

AU - Moreno, V.

AU - Vidal, X.

AU - Podzamczer, D.

AU - Gudiol, F.

AU - Casanova, A.

AU - Clotet, B.

AU - Jou, A.

AU - Miró, J. M.

AU - Gatell, J. M.

AU - Aznar, E.

AU - Vázquez, J. M.Martinez

AU - Ocaña, I.

AU - Camps, I. Ruiz

AU - Cisterna, R.

AU - Santamaria, J. M.

AU - Cosín, J.

AU - Gómez, J.

AU - Vázquez, J. J.

AU - Aguado, A. Gil

AU - Valencia, M. E.

AU - Buzón, L.

AU - Lahoz, J. M.González

AU - Polo, R. M.

AU - Moreno, V.

AU - Zulaica, D.

AU - Arrondo, F. Rodriguez

PY - 1991/1/1

Y1 - 1991/1/1

N2 - © 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.

AB - © 1991, Lancet Publishing Group. All rights reserved. To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicentre, placebo-controlled, prospectively randomised trial was conducted in CDC group III HIV-infected individuals between February, 1988, and October, 1989. Mean treatment time was 39 weeks (range 6-52); 152 individuals were enrolled, of whom 133 could be evaluated. The two treatment groups were similar at baseline and 66% of all subjects had intravenous drug abuse as the main risk factor for HIV infection. Ribavirin was given at a dose of 15 mg/kg daily by mouth (average daily dose 1000 mg). 9 of 67 patients in the placebo group (13-4%) progressed to CDC Groups IVA, C1, or D vs 6 of 66 (9%) in the ribavirin group. Progressions to group IVC2 were 7 (104%) and 9 (13-6%), respectively. These differences are not statistically significant. There were no clinically or statistically significant differences in CD4 cell counts, total lymphocytes, total white cells, or CD4/CD8 ratios between the two groups during treatment, and no clinically important side-effects were noted.

U2 - 10.1016/0140-6736(91)90003-8

DO - 10.1016/0140-6736(91)90003-8

M3 - Article

VL - 338

SP - 6

EP - 9

IS - 8758

ER -